Buscar
Mostrando ítems 1-10 de 57
Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer’s disease
(Taylor and Francis Ltd, 2019)
Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies
(BioMed Central, 2016)
BACKGROUND: The effect of glucagon-like peptide-1(GLP-1) receptor agonists on heart failure remains uncertain. We therefore conducted a systematic review to assess the possible impact of GLP-1 agonists on heart failure or ...
Glucagon-like Peptide-1 Receptor Agonists (glp-1ras) In The Brain-adipocyte Axis
(Adis Int LtdNorthcote, 2017)
Metabolic effects of antidiabetic drugs on adipocytes and adipokine expression
(Wiley-Liss Inc., 2019)
Anti-inflammatory properties of antidiabetic drugs: a “promised land” in the COVID-19 era?
Inflammation is implicated in the development and severity of the coronavirus disease 2019
(COVID-19), as well as in the pathophysiology of diabetes. Diabetes, especially when
uncontrolled, is also recognized as an ...
SGLT2i and GLP-1RA in Cardiometabolic and Renal Diseases: From Glycemic Control to Adipose Tissue Inflammation and Senescence
(Hindawi, 2021)
Background. Over the last few years, the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) has increased substantially in medical practice due to their ...
Regulation of Na(+)/H(+) exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells
(AMER PHYSIOLOGICAL SOC, 2009)
Carraro-Lacroix LR, Malnic G, Girardi AC. Regulation of Na(+)/H(+) exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Renal Physiol 297: F1647-F1655, 2009. ...